Artificial Pancreas With Carbohydrate Suggestion for Patients With Type 1 Diabetes Prone to Hypoglycemia

Sponsor

Hospital Clinic of Barcelona (Other)

Overall Status

Completed

CT.gov ID

NCT05628662

Collaborator

Universitat Politècnica de València (Other), Universitat de Girona (Other)

Enrollment

Location

Arm

5.5

Actual Duration (Months)

2.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Achieving near-normoglycemia has been established as the main objective for most patients with Type 1 Diabetes (T1D). Automated insulin delivery (AID) systems, the so-called artificial pancreas (AP) or closed-loop systems, may represent the ideal solution, especially for patients not reaching the therapeutic goals with multiples doses of insulin or open-loop delivery systems. Despite the advances in recent years that have proven the efficacy and safety of these devices in clinical trials and clinical practice settings, such evidence cannot be extrapolated to highly unstable patients, as problematic hypoglycemia remains an exclusion criterion in most of the trials.

The SAFE-AP system is a single-hormone hybrid closed-loop controller based on a proportional derivative with an insulin feedback controller that integrates a safety layer with insulin-on-board constraints and sliding mode reference conditioning. The hybrid closed-loop system includes a second safety feedback loop with a controller that triggers carbohydrate recommendations to the patient. Both control loops are coordinated to ensure that the counter-regulatory effect of rescue carbohydrates is not counteracted with insulin. Such system has been previously proven effective in unannounced exercise, one of the main challenges in AID systems development. Additionally, the algorithm has been recently tailored to achieve a better control in the subgroup of T1D patients prone to hypoglycemia.

In this project, a rigorous clinical testing of the SAFE-AP system will be carried out in 12 patients with T1D and problematic hypoglycemia, despite treatment with continuous subcutaneous insulin infusion. The safety and performance of the system will be evaluated in a 32-hour pilot study, including 4 meals, one overnight period and 2 unannounced aerobic exercise sessions. The study will be performed in a hospital setting with the on-site supervision of a specialized nurse and a diabetologist, as well as an engineer in remote control.

Condition or Disease	Intervention/Treatment	Phase
Type 1 Diabetes Mellitus Prone to Hypoglycemia	Device: Automated Insulin Delivery System (SAFE-AP)	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

12 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Pilot Study Evaluating the Safety and Performance of an Artificial Pancreas With Carbohydrate Suggestion for Patients With Type 1 Diabetes Prone to Hypoglycemia

Actual Study Start Date :

Oct 22, 2021

Actual Primary Completion Date :

Apr 6, 2022

Actual Study Completion Date :

Apr 6, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Automated Insulin Delivery System (SAFE-AP) Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFE-AP) based on blood glucose estimations from CGM.	Device: Automated Insulin Delivery System (SAFE-AP) Each subject will undergo a 32-hour in-hospital study, including 4 meals (60 grams of carbohydrates each, except 50 grams for breakfast), one overnight period and 2 unannounced aerobic exercise sessions. Each exercise session consists of three 15-minute sets on a cycle ergometer at 70% of maximum heart rate with 5 minutes of rest between sets.

Arm

Intervention/Treatment

Experimental: Automated Insulin Delivery System (SAFE-AP)

Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFE-AP) based on blood glucose estimations from CGM.

Device: Automated Insulin Delivery System (SAFE-AP)

Each subject will undergo a 32-hour in-hospital study, including 4 meals (60 grams of carbohydrates each, except 50 grams for breakfast), one overnight period and 2 unannounced aerobic exercise sessions. Each exercise session consists of three 15-minute sets on a cycle ergometer at 70% of maximum heart rate with 5 minutes of rest between sets.

Outcome Measures

Primary Outcome Measures

Percentage of CGM time in glucose range 70-180 mg/dl during the study. [From 12 AM of the first day of study until 4 PM of the second day of study]

Secondary Outcome Measures

Percentage of CGM time in glucose range 70-180 mg/dl during nighttime [From 22 PM of the first day of study until 7 AM of the second day of study]
Percentage of CGM time in glucose range 70-180 mg/dl during exercise and recovery [Defined as 3 hours after exercise initiation]
Percentage of CGM time in glucose range 70-180 mg/dl during postprandial period [Defined as 4 hours since mealtime]
Percentage of CGM time in hypoglycemia (<70 mg/dL and <54 mg/dL) during the study [From 22 PM of the first day of study until 7 AM of the second day of study]
Percentage of CGM time in hypoglycemia (<70 mg/dL and <54 mg/dL) during nighttime [From 22 PM of the first day of study until 7 AM of the second day of study]
Percentage of CGM time in hypoglycemia (<70 mg/dL and <54 mg/dL) during exercise and recovery [Defined as 3 hours after exercise initiation]
Percentage of CGM time in hypoglycemia (<70 mg/dL and <54 mg/dL) during postprandial period [Defined as 4 hours since mealtime]
Percentage of CGM time in hyperglycemia (>180 mg/dL and >250 mg/dL) during the study [From 22 PM of the first day of study until 7 AM of the second day of study]
Percentage of CGM time in hyperglycemia (>180 mg/dL and >250 mg/dL) during nighttime [From 22 PM of the first day of study until 7 AM of the second day of study]
Percentage of CGM time in hyperglycemia (>180 mg/dL and >250 mg/dL) during exercise and recovery [Defined as 3 hours after exercise initiation]
Percentage of CGM time in hyperglycemia (>180 mg/dL and >250 mg/dL) during postprandial period [Defined as 4 hours since mealtime]
Glucose coefficient of variation during the study [From 22 PM of the first day of study until 7 AM of the second day of study]
Number of hypoglycemic events [From 22 PM of the first day of study until 7 AM of the second day of study]
Defined as sensor glucose <70 mg/dL during 15 minutes or symptomatic hypoglycemia confirmed with plasma glucose
Number of carbohydrate rescue events during the study [From 22 PM of the first day of study until 7 AM of the second day of study]
Number of acute metabolic events during the study [From 22 PM of the first day of study until 7 AM of the second day of study]
Defined as severe hypoglycemia and diabetic ketoacidosis

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Subjects aged 18 or more with Type 1 Diabetes for at least 5 years.
Treated with continuous subcutaneous insulin infusion (CSII) for at least six months.
Trained to carbohydrate counting.
Subjects prone to hypoglycemia, despite optimal diabetes management and hypoglycemia-specific education programs, as defined by >4 hypoglycemic episodes per week and at least one of the following:

Occurrence of at least 2 severe hypoglycemic episodes during the last 2 years (need for third party).
Occurrence of at least 1 severe hypoglycemic episode during the last 2 years and high glycemic variability (coefficient of variation >36%).
Impaired awareness of hypoglycemia (Clarke test ≥4).

Physical examination, laboratory data and EKG without alterations. Abnormalities considered clinically irrelevant by the investigator will not be exclusion criteria.
Negative SARS-CoV-2 PCR test performed at arrival.
Subject willing to wear the SAFE-AP system continuously throughout the study.

Exclusion Criteria:

Pregnancy and breastfeeding.
History of drug or alcohol abuse.
Progressive fatal disease.
Clinically relevant microvascular complications (macroalbuminuria, pre-proliferative and proliferative retinopathy), cardiovascular, hepatic, neurological, endocrine or other systematic, apart from T1D, which may hamper the implementation of the clinical study protocol or interpretation of results study.
Scheduled surgery during the study period.
Mental conditions that prevent the subject to understand the nature, purpose and possible consequences of the study.
Subjects who are unlikely to meet the clinical study protocol, eg. uncooperative attitude, inability to return for follow-up visits, or poor probability of completing the study.
Using an experimental drug or device during the past 30 days.